Lara Sullivan, Pyxis Oncology CEO

Small SPAC to tiny sale: Apex­i­gen sprints to Pyx­is On­col­o­gy in $16M ex­it

Pyx­is On­col­o­gy, the pub­lic Boston biotech breath­ing life in­to Pfiz­er’s an­ti­body-drug con­ju­gates plat­form, will buy Apex­i­gen, a small on­col­o­gy out­fit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.